Bachem plans to build a large-scale peptide production facility in Sisslerfeld
Total investment amounts to more than CHF 500 million
Advertisement
Bachem announced the signing of an agreement to supply large volumes of peptides. Therefore, Bachem will invest more than CHF 500 million in the greenfield project in Sisslerfeld. The strategic collaboration includes pre-payments and long-term commitments. Start of commercial production at the new site in Sisslerfeld is expected in 2030. The collaboration partners have agreed not to disclose any further details.
"Demand for peptides as active pharmaceutical ingredients remains high, and long-term supply agreements are essential to guarantee reliability for our customers and their patients while ensuring disciplined capacity expansion,” says Dr. Anne-Kathrin Stoller, CEO of Bachem. She continues: “This agreement further strengthens Bachem’s planning security beyond 2030 and enables us to responsibly coordinate investments across our entire manufacturing network, including Sisslerfeld.”
Bachem is implementing a program to expand capacity across its entire network, including facilities designed for high-volume production of peptides and oligonucleotides, thereby strengthening its position as a leading global partner for TIDES. Bachem operates as a global network of manufacturing sites, including Bubendorf (Switzerland), Sisslerfeld (Switzerland), Vionnaz (Switzerland), Vista (USA), Torrance (USA) and St. Helens (UK).
Other news from the department business & finance
